February 20, 2013 09:16 ET

Market Trade Alerts Issued for CWNM, SWVI, YFRM, RARS

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by

CORAL SPRINGS, FL--(Marketwire - Feb 20, 2013) - reports on Active Companies to watch today: Crown Marketing (OTCQB: CWNM), Swingplane Ventures, Inc. (OTCQB: SWVI), YaFarm Technologies, Inc. (PINKSHEETS: YFRM), Rarus Technologies Inc. (OTCQB: RARS).

Crown Marketing (OTCQB: CWNM) issued this morning announcing that patents for its Controlled Drug Delivery Technology (CDDT) have been approved and registered in Mexico. Mexico's pharmaceutical industry faces unique challenges. According to an American Enterprise Institute study, Mexico's $15.5 billion market is plagued by counterfeit goods. Illicit activity in Mexico's pharmaceutical industry is estimated at roughly USD 1.9 billion per year -- with counterfeiting representing 81 percent of that illicit market. This is a situation where CWNM believes its unique technology could have a significant impact. For more details regarding Crown's CDDT applications, go to 

To read full news release and all the latest headlines for Crown, go to

Swingplane Ventures, Inc. (OTCQB: SWVI) (the "Company" or "Swingplane") released an update yesterday regarding information pertaining to the Algarrobo property. SWVI's Algarrobo Property is an Iron Oxide-Copper-Gold (IOCG) property located approximately 850 km north of Santiago, in the III Region, Province of Copiapo, Chile. The city of Copiapo is located approximately 43 km to the southeast of the Property, with the small port city of Caldera 25 km to the east. The Property consists of 32 tenures, comprising a total of 6,161 ha (15,224 acres).

YaFarm Technologies, Inc. (PINKSHEETS: YFRM) announced yesterday it has reached several important milestones since signing the definitive agreement with The Integrative Stem Cell Institute (ISCI). YaFarm has appointed top level management for ISCI by announcing David Audley as CEO and Juan A. Castillo as Chairman of the Board of Directors. Dr. Castillo is a pioneer in regenerative medicine and has successfully treated over 250 patients using adult stem cells, while Mr. Audley successfully managed the International Cellular Medicine Society (ICMS) for nearly 4 years.

Rarus Technologies Inc. (OTCQB: RARS) is an emerging technology company focused on establishing an innovative business model intended to bridge cutting-edge social media and e-commerce into a marketplace that connects friends, family, consumers, and vendors in new and exciting ways. RARS experienced heavy trading yesterday closing up over 100% on 45.14Million shares traded. is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit for more details. 

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information